Immune Response to Seasonal Influenza Vaccine in Patients With Relapsing-Remitting Multiple Sclerosis Receiving Long-Term Daclizumab Beta

International Journal of MS Care - United States
doi 10.7224/1537-2073.2016-026
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Consortium of Multiple Sclerosis Centers

Related search

Cognitive Profile of Patients With Relapsing Remitting Multiple Sclerosis

Arquivos de Neuro-Psiquiatria
Biological PsychiatryNeurology
1999English

Progressive Gray Matter Damage in Patients With Relapsing-Remitting Multiple Sclerosis

Archives of Neurology
2005English

Long-Term Evaluation of NEDA-3 Status in Relapsing-Remitting Multiple Sclerosis Patients After Switching From Natalizumab to Fingolimod

Therapeutic Advances in Neurological Disorders
NeurologyPharmacology
2018English

Intestinal Permeability in Relapsing-Remitting Multiple Sclerosis

Neurotherapeutics
NeurologyPharmacology
2017English

Work Participation and Executive Abilities in Patients With Relapsing-Remitting Multiple Sclerosis

PLoS ONE
Multidisciplinary
2015English

Oxidative Stress Related to Iron Metabolism in Relapsing Remitting Multiple Sclerosis Patients With Low Disability

Frontiers in Neuroscience
Neuroscience
2019English

Health State Utilities in Patients With Relapsing Remitting Multiple Sclerosis Treated With Cladribine Tablets

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Long-Term Safety and Efficacy of Natalizumab in Relapsing-Remitting Multiple Sclerosis: Impact on Quality of Life

Patient Related Outcome Measures
2014English

Progressive Multifocal Leukoencephalopathy and Relapsing-Remitting Multiple Sclerosis

Archives of Neurology
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy